WLDS: The Activist Who Became the Bank

The short version

In fourteen days this summer, an Israeli investor named Nissim Daniel bought a quarter of a Nasdaq-listed company for $951,425, fought its board, won four of seven seats, and then sold every share he owned.

None of that is inferred. His name, what he paid, the prices he sold at and the agreement he signed are all in public filings, and this piece links every one.

The part almost nobody has noticed is what he kept. Start with who is who, because that is where this story usually gets lost.

Three parties, and the one thing everyone gets wrong

Almost all the confusion about this story comes from blurring three separate parties into two. They are:

### The warrants were never his

The 1,760,000 warrants belong to that third party, the institutional investor, not to Nissim Daniel. The ordinary ones exercise at $3.16.

Daniel holds no warrants and, since August 11, no shares. He went to court to block the deal that created those warrants, which is the clearest possible proof the two are not the same person.

What he holds instead is a promise to lend $12 million, at a conversion price nobody has agreed yet. That difference is the whole article: the warrant strike is a number you can price today, and his is not.

And nobody forced him to sell. No agreement required it, and the settlement did not ask for his shares. He chose to sell, three days after winning the board seats he came for. Why he would do that is the question this piece exists to answer.

The timeline, in nine lines

Was the settlement a meeting in the middle? Yes, and both sides paid. He got the board seats he demanded and dropped the lawsuit. The company kept its money-raise, bought two years of quiet, and gained a funding backstop. Neither side got everything.

So what was the point, and is it good for the stock?

Fair questions, and the piece owes you plain answers before the detail.

Does he still own anything?

No. Not one share and not one warrant. Since August 11 his only remaining connection to this company is a promise to lend it $12 million, and even that only triggers if the board asks.

The warrants people keep attaching to him were never his. They belong to the outside investor who bought the July share issue, and Daniel sued to stop that issue happening.

Who actually made money?

That last row is the honest answer to the uncomfortable version of your question.

So is this farming retail?

Not in the sense of anything improper. Every step was disclosed in a public filing, the activist took a real legal risk, and the company got money it genuinely needs. Nobody has been accused of anything and we are not accusing them.

But look at the effect rather than the intent. The pattern that has actually run twice now is: a patent announcement, a violent spike, and the company selling stock into that spike. The share count went from 707,463 to roughly 2,460,394 in eighteen months. The people who bought those spikes funded the company and own a third of what they used to.

That is the mechanism to understand. Not a conspiracy, and not free money either. It is a company with real patents, almost no revenue and a large appetite for capital, which is a machine that converts enthusiasm into balance sheet.

So is it good for the stock?

Genuinely split, and it depends entirely on the next number nobody has seen.

Better than it was: the company has $19.5 million liquid, almost no debt, a funding commitment that removes the risk of dying, and four financially experienced directors who were not there a month ago.

Worse than it looks: 1,760,000 warrants sit over a 2,460,394 share count, and a $12 million convertible sits over a $7.4 million company at a price that has not been agreed. Both of those are paid for in shares, by you.

### The one number that settles it

What price does the $12 million convert at?

Near the market when it is drawn, and this was a company getting itself funded and governed. At a steep discount, or on a price that floats down with the stock, and it was something else. That number does not exist yet, which is exactly why this is a story to watch rather than a conclusion to draw.

The rest of this piece is how each of those answers was arrived at, and where to look for that number when it appears.

The activist, in detail

Daniel's side is two entities acting as one. J.B.D Innovation Ltd., which he solely owns and directs, did the buying: 477,361 shares for about $835,859. Victor Tshuva & Co. Law Offices holds a further 66,000 at $1.751 each, acquired from J.B.D under an agreement dated July 26.

They filed as a group and act in concert, which is why a single 24.82% figure covers both.

Under a million dollars bought a quarter of a Nasdaq-listed company. That single fact is why everything after it was possible.

Simply put: what a Schedule 13D means

There are two forms for crossing 5% of a company. One says "I am just investing." The other says "I intend to change something." He filed the second one.

What he actually demanded, in plain terms

On July 27, four days after buying, the group sent the company a demand letter under Israeli law, requiring it to call a special shareholder meeting. Legal language obscures what was being asked, so here is each proposal and what it does:

Read as a set, that is not a request for influence. It is a request for the board. Change the removal rules, remove four of five, install four of your own, and pay them. If all four had passed, the company would have had a new controlling board without buying a single additional share.

The company answered by selling stock, and a judge stopped it

On July 31, four days after the demand letter, the company agreed to sell a single unnamed institutional investor:

Against 2,189,469 shares in existence, that is close to doubling the company.

Why warrants, and who gains

A warrant is a coupon to buy a share later at a price fixed today. The two kinds above do different jobs.

Pre-funded warrants are not really warrants. The buyer paid $3.2849, essentially the full share price, and owes a token amount to convert. They are shares wearing a different hat, and investors take them because an unexercised warrant does not count toward the ownership percentage that triggers public reporting.

Ordinary warrants are the real coupons. A million of them at $3.16, worthless below that price and valuable above it.

Existing shareholders get the bill, because every coupon eventually becomes a share competing with theirs.

What the warrants are actually worth

Share counts understate this. In money:

Our $3,284,924 matches the roughly $3.3 million gross the company reported on August 10, which is a useful check that the terms are being read correctly.

For the holder, the ordinary warrants are currently worthless: they exercise at $3.16 and the stock is $3.02. They are a bet, not an asset, and they only pay if the stock rises.

For you, the cost is the share count. 1,760,000 warrant shares sit behind roughly 2,460,394 that exist, which is 72% more stock. Fully exercised, today's holders would own 58.3% of the company they own all of now.

That is the trade the placement made on your behalf: $3.3 million in the door today, at the cost of up to 72% more shares tomorrow.

It does one more thing, which is why a judge got involved: new shares in friendly hands shrink a hostile shareholder's percentage.

On August 2 the Economic Department of the Haifa District Court issued an interim order, on an ex parte basis, temporarily prohibiting the company from taking any action to advance the placement or to "effect any change in the Company's capital structure."

For five days an outside shareholder had legally frozen this company's ability to issue stock. A hearing was set for August 16. It never happened.

The settlement: what each side got

On August 7 they signed a Cooperation Agreement. Both sides gave something real.

Five directors, minus two who leave, plus four who arrive, equals seven. Four of those seven are his.

He asked for four seats and got four seats. In exchange he agreed to stay quiet for two years.

Who the four new directors are

"His nominees" is vague, so here is who they actually are, from the company's own filing. All four qualify as independent under Nasdaq rules.

Two things stand out, and neither needs interpreting.

Not one comes from wearables, neurotech or consumer hardware. They are accountants, CFOs and lawyers. Their common thread is small-cap capital markets: raising money, structuring deals, sitting on the boards of very small Nasdaq companies.

Two of the four already serve together on the board of Rail Vision.

Whatever this board was assembled to do, its centre of gravity is financial and legal, not technical.

Three days after putting those four people in the room, he did something that makes no sense at all until you see what else he signed.

Then he sold everything

The share sale closed on August 10. The same day, this began:

From the final filing:

On August 10, 2026, the Reporting Persons sold an aggregate of 258,126 Ordinary Shares in the open market and on August 11, 2026, the Reporting Persons sold an aggregate of 123,235 Ordinary Shares in the open market. Accordingly, as of August 11, 2026, none of the Reporting Persons beneficially owns any securities of the Issuer

The prices are disclosed. J.B.D sold at weighted averages of $3.76 on August 10 and $2.97 on August 11.

Here is the arithmetic that matters:

The final two days alone returned more than his entire original investment, and he had already sold 162,000 shares before those two days even started.

So why sell three days after winning?

Read as a sequence this is baffling. Read as a strategy, every step lines up.

A 24.82% stake in a company like this looks powerful and is not. Here is what he actually held, against what he traded it for:

### The sentence that explains it

If you expect to buy a large piece of a company cheaply later, you do not want to be holding expensive shares in it now.

Every share he held at $3.76 would have been diluted by his own conversion. Selling was not abandoning the position. It was clearing the way for it.

Lending on terms that convert into ownership, while holding board seats, is a recognised structure called loan-to-own. It is legal, common, and fully disclosed here.

We are describing the shape of the arrangement, which is public record. We are not claiming to know Nissim Daniel's intentions, and no filing states them. He may simply have taken a profit and left a backstop behind. The two-year standstill he accepted, barring him from influencing governance until August 2028, genuinely cuts against the aggressive reading.

Both readings fit the same documents, and a shareholder has to price the result either way. So here is the instrument he actually kept.

The $12 million that changes the shape of this

On the same day he signed the settlement, J.B.D signed a side letter committing it, irrevocably and for 24 months, to fund the company if the board determines in good faith that it cannot cover the next 24 months of operations.

The amount is not less than $12,000,000. The form is debt convertible into ordinary shares. And the terms are the whole story:

The structure and commercial terms of such convertible debt financing, including the amount and timing of funding, interest rate, if applicable, maturity, repayment terms, conversion mechanics ... will be negotiated and agreed in good faith between JBD and the Board then in office, including the directors appointed pursuant to the Cooperation Agreement.

Read the last clause slowly. The price at which that $12 million becomes shares has not been set. It gets negotiated later, between J.B.D and a board on which four of seven directors are J.B.D's nominees.

Both edges of this are real and both should be said.

It is genuinely good for the company. A business burning $6.6 million a year now has a contractual backstop for 24 months, which removes the financing cliff that kills companies like this. It is probably why the stock did not simply collapse when a 24.82% holder sold out.

It is a real risk for shareholders. The conversion price is unset, the negotiation sits with a board he nominated, and $12 million against a $7.4 million company is not a rounding error. Nothing has been drawn and no terms exist yet, so this is a structure to watch rather than a harm that has happened.

What happens next

The story is not finished. Three things resolve it, and all three will appear in public filings.

1. Does the board declare a funding need? The $12 million only triggers if the board determines, in good faith, that the company cannot fund 24 months of operations. With roughly $19.5 million liquid and a $6.6 million burn, that moment is not imminent, but it is arithmetically on the calendar. Watch for it in a 6-K.

2. What is the conversion price? This is the whole ballgame. The side letter explicitly leaves interest rate, maturity and conversion mechanics to be negotiated later. A conversion price near the market at the time is ordinary financing. A conversion price at a steep discount, or one that floats down with the stock, is something else entirely. This single number will tell you whose interests the new board serves.

3. Do the four new directors act independently? They qualify as independent under Nasdaq rules and they have their own reputations across a dozen other listed companies. The test is not what they are labelled. It is what they approve.

### The uncomfortable structural fact

When that financing is negotiated, J.B.D will be on one side of the table, and a board it nominated four of seven members of will be on the other. That is disclosed, it is legal, and both sides have legal duties. It is also a conflict a shareholder should price rather than ignore.

Why any of this was possible

Zoom out and the fourteen days stop looking like an anomaly.

On September 10, 2025 the company published a release titled "Wearable Devices Secures U.S. Patent for Breakthrough Voice and Gesture Control Technology, Enhancing Leadership in AI Wearables Market."

The stock had closed at $3.06. It opened at $20.97 on 96.7 million shares and reached $34.20 two days later.

What happened next is the pattern:

Three offerings in fifteen days, directly into the spike.

It worked, as corporate finance. Shareholders' equity went from $3,860,000 to $18,553,000 in a year. The company turned a press release into a balance sheet. The share count is the receipt for who paid:

Three times as many shares in eighteen months. And the dilution is visible in real time inside the 13D amendments: between August 2 and August 7 the group's holding fell from 17.42% to 15.50% without them selling one share. The denominator moved.

A further patent press release was issued on August 11.

That is how a company earning $647,000 a year came to be sitting on $19.5 million. Which leaves the obvious question: if the money is really there, why will the market not pay for it?

Why the market pays less than the cash

The company holds $19.53 million of current assets against $1.44 million of total debts, and the market values the whole business at about $7.4 million. That is roughly 42 cents for every dollar of cash and near-cash inside it.

There are only two readings, and they are not equally supported.

The market is wrong. You are buying roughly $17.7 million of mostly cash for $7.4 million, with the patents thrown in.

The market is right. Companies do not wind up and hand the cash back. This one spends $6.6 million a year and takes in $647,000. A discount to cash is not an oversight, it is a forecast that the cash gets consumed rather than returned.

The second reading has the stronger evidence, because that is precisely what happened to the last raise. But the discount is unusually large, and that is what makes this interesting rather than simply bad.

Where it goes from here

Four paths. Our read, with numbers on them rather than a hedge.

### The most likely

It grinds on and dilutes. Revenue stays small, the board declares a funding need, the $12 million is drawn and converts at a price agreed later. The company survives comfortably. The share count rises and the stock does not do well.

Roughly 55%, for one unglamorous reason: it is what the last two years already did, twice, and nothing since has broken the pattern.

The board imposes capital discipline, about 20%. Four financially sophisticated directors change how money gets raised. The genuine wildcard, free to watch for, and it would show up plainly in the filings.

A licensing deal lands, about 15%. What the patents point at, and the only path to a large re-rating. Almost entirely outside the company's control.

It runs out of road, about 10%. Low specifically because of the $12 million.

What would tell you which

• Revenue at a few million a year. An invoice run rate, not a milestone. That one number changes the argument.
• A named licensing partner. One agreement with a company you have heard of validates everything else.
• A rally with no offering behind it. The most convincing thing management could do on the next spike is nothing.
• The conversion price when the $12 million is drawn. It will tell you whose interests the new board serves.
• Insider buying. Nobody involved has bought in the open market on the way down.

What the chart says

That is the business. This is the tape, which on a stock like this has rules of its own. All figures are calculated from our own daily bars through August 12, on 251 sessions.

The support that is actually there is $2.77 to $2.87, where the 20 EMA, 21 EMA, 200 EMA and 20-day simple average all sit within four percent of each other. Four methods agreeing is what makes a level worth respecting. Below it, the structural floor is the $2.37 to $2.50 base built on July 31, August 3 and August 11. Lose $2.37 and the sequence that began on July 23 is broken.

The 50 EMA is not where most people think. It sits at $2.22 against a $3.02 close, so price is 36% above it. A stop just below that average is a 28% stop, not a tight one. That is what happens after a stock triples in three weeks.

The confirmation has not fired. The 9 EMA is $3.24 and price closed below it at $3.02. A daily close back above $3.24, with that average turning up, is the first real signal available. Until then the pullback is still a pullback.

Why a 7% stop does not work here

ATR(14) is $1.37, which is 45.3% of the share price. This stock's ordinary daily range is nearly half its own value.

A 7% stop sits 0.15 of one average day's range below the close. Tested against what actually happened, it would have been hit on four of the last eight sessions: August 3, 5, 6 and 11. August 6 was the day the stock closed up 47%.

A fixed percentage stop is a volatility filter wearing a risk-management costume. Seven percent is generous on a utility and meaningless on a stock whose average day is 45%. A stop that respects the structure sits below $2.37, roughly 21% away. If that is too much, the answer is a smaller position, not a tighter stop.

The chart and the filings agree here, which is unusual. Both say the same thing: size small and watch. No amount of entry precision solves this, because the conversion price on that $12 million will move the stock more than any moving average.

The bottom line

A named investor spent $951,425 on a quarter of a company, fought it in court, won four of seven board seats, sold every share at roughly double his money, and left behind a promise to lend it more than the whole business is worth, at a price nobody has agreed yet, to a board he chose.

Every step was legal and every step was disclosed. The company came out better funded. The people who owned it came out owning less of it.

Whatever he concluded about the equity, he did not conclude it was the best place to be. That is the part worth sitting with.

References

SEC filings (Wearable Devices Ltd., CIK 0001887673)

• Schedule 13D, July 27, 2026: J.B.D Innovation, Nissim Daniel, Victor Tshuva & Co., the 543,361 shares, the $951,425 and the demand letter
• Schedule 13D/A, August 12, 2026: the August 10 and 11 sales, the weighted average prices, and the zero position
• Form 6-K, July 27, 2026: the company confirming the demand to remove four of five directors
• Form 6-K, August 4, 2026: the Haifa District Court order freezing the placement
• Form 6-K, August 5, 2026: the placement terms, shares, pre-funded warrants and ordinary warrants
• Form 6-K, August 10, 2026: the Cooperation Agreement, the two-year standstill, the four director biographies, and the $12,000,000 convertible financing commitment
• Form 6-K, September 10, 2025: the patent release that preceded the move to $34.20
• Prospectus supplement, September 12, 2025 and September 15, 2025: the two registered direct offerings
• Prospectus supplement, September 25, 2025: the $7,400,000 at-the-market facility
• Complete EDGAR filing history

Notes on the numbers

Revenue, net loss, operating cash flow, assets, liabilities and shareholders' equity are FY2025 figures from the company's own filed XBRL data. Share counts are as disclosed: 707,463 at December 31, 2024, and 2,189,469 at June 17, 2026 per the Schedule 13D, which cites the company's Form 6-K of that date. The August 7 figure of approximately 2,460,394 is implied by the same 381,361 shares being reported as 15.50% rather than 17.42%, and is an estimate. Estimated current equity applies roughly seven months of the FY2025 burn rate to the audited December 31, 2025 figure and adds the $3.3 million placement; it is an estimate, not a reported number. The $1,105,251 realised on August 10 and 11 is calculated from the share counts and weighted average prices in the final Schedule 13D/A. Prices, volumes, the 52-week range and the pre-event average daily volume are from The Desperate Trader's own market data. All moving averages, the Average True Range and the stop-distance tests are calculated by us from those daily bars through August 12, 2026, using 251 sessions of history; EMAs are standard exponential averages and ATR is the 14-period average of true range. Verdicts, the probability estimates on the four paths, and the reading of the strategy are our opinion, clearly labelled as such in the text.

This is research and commentary, not investment advice, and not an allegation of wrongdoing by any person or firm named. Every action described above was disclosed in public filings.